Chess Therapeutics, LLC

Chess Therapeutics is an oncology focused biotechnology company developing novel microtubule targeted drugs with a distinct spectrum of anti-cancer activity and pharmacologic properties compared with other microtubule targeted agents. The company’s drug candidates effectively cross the blood-brain barrier, have potential for oral delivery, and exhibit a favorable toxicity profile. They demonstrate preferential and potent activity against the aggressive brain cancer glioblastoma and cancers that carry the “cancer driving” gene mutation BRAF (melanoma, colorectal cancer, lung adenocarcinoma).